Abbott Laboratories (ABT) official guidance

For the third quarter, we forecast adjusted earnings per share of $1.38-$1.46.

Based on current rates, we expect exchange to have a positive impact of approximately 1% on full year sales, which includes our expectation for exchange to have a negative impact of approximately 1% on third quarter sales.

Based on current rates, we expect exchange to have a positive impact of approximately 1% on full year sales, which includes our expectation for exchange to have a negative impact of approximately 1% on third quarter sales.

Considering our second quarter results and updated outlook for the remainder of the year, we are reaffirming our full year guidance for comparable sales growth of 6.5%-7.5% and raising our EPS guidance range to $5.45-$5.60.

We continue to expect cancer diagnostics growth in the second half of the year to be higher than the first half, supported by increasing volumes from care gap programs, recently launched tests, and continued international adoption.

We're still forecasting a decline in the China business, but much, much lower, mid-single digits.

I expect global EP growth to accelerate. It's in the teens right now. It'll accelerate in the second half for sure and outperforming the market.

Our deal model that we put together to support the acquisition for 2026 had mid-teens. I feel confident that we'll achieve that.

There's a lot of proof points here, Joanne, in terms of being able to feel confident about not only the acceleration in the second half, but establishing this kind of 2%-4% range here for this business.

Yeah. Listen, I expect structural heart by the end of this year to be in that kind of mid to high single-digit growth rate back to where we were before.

We have momentum building across the portfolio and clear line of sight to the key drivers of sales growth acceleration that are forecasted in the second half.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60.

For the second quarter, we forecast adjusted earnings per share of $1.25-$1.31.

For the second quarter, we expect exchange to have relatively neutral impact on sales.

As we communicated at the time of the acquisition announcement, we forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott's long-term sales growth rate.

As we look forward to the second quarter, we expect CGM to return to double-digit growth.

I expect to be getting the full year for our Core Lab business is kind of in that mid-single-digit growth rate.

I think that includes growing faster than the market, by the exit of this year.

Med tech business, low double digits, our pharma business above 7%. These are businesses that have consistently and reliably delivered this type of performance.

Med tech business, low double digits, our pharma business above 7%. These are businesses that have consistently and reliably delivered this type of performance.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.

And we forecast our adjusted tax rate to be in the range of 15%-16%.

Turning to our outlook for 2026, today we issued guidance for full-year adjusted earnings per share of $5.55-$5.80, which reflects 10% growth at the midpoint of the range and contemplates an adjusted earnings per share forecast of $1.12-$1.18 for the first quarter.

Based on current rates, we expect exchange to have a favorable impact of around 1% on full-year reported sales, which includes an expected favorable impact around 3% on first-quarter reported sales.

Expect to do more of the same, focus on the things that are strategically aligned and the execution here to where we continue to look at a 50-70 basis-point improvement in operating margins every year, and that's kind of what we've got built into this, and fully expect we'll do that through both gross margin expansion as we've done, but continue to gain leverage in the P&L where appropriate, so that's kind of how we've constructed that double-digit earnings.

I think the math will work out to what you just kind of highlighted there in the kind of low teens.

So I'd say the outlook of that business is we will be, I'd say, mid-single digit growth this year versus kind of where we were in 2025.

My expectation with that business going forward is, listen, I'm not expecting big growth out of it. All I need for it is to be pretty stable, and it being stable, I get to have the other parts of the portfolio that are accelerating.

So I'd say the outlook of that business is we will be, I'd say, mid-single digit growth this year versus kind of where we were in 2025. And if you remove China again, this is a full year view. If you remove China, then you're in that kind of 7%-8% kind of range.

We expect performance in the nutrition to remain challenged in the first half of the year, with a return to growth in the second half.

We expect performance in the nutrition to remain challenged in the first half of the year, with a return to growth in the second half.

In summary, we delivered another very good quarter. Our pipeline has been highly productive and continues to fuel growth, and we remain on track to deliver high single-digit organic sales growth and double-digit EPS growth.

Yeah, Larry. Yeah, I'm very comfortable with consensus. In fact, you know this is a question that was asked last year in our Q3 earnings call, and consensus for 2025 at that time was 7.5%, EPS growth of 10%. That's the same consensus estimates that we have today. I was comfortable with delivering that type of growth at this time last year, and I'm comfortable again today forecasting to deliver that type of growth next year.

Based on current rates, we expect exchange to have a favorable impact of approximately 1.5% on our fourth quarter reported sales.

Abbott also reaffirms the midpoint of the previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, which reflects double-digit growth at the midpoint.

Abbott reaffirms previously provided full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales, or 6.0% to 7.0%, when including COVID-19 testing-related sales.

Abbott reaffirms previously provided full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales, or 6.0% to 7.0%, when including COVID-19 testing-related sales.